Citi analyst David Lebowitz raised the firm’s price target on PTC Therapeutics to $18 from $17 and keeps a Sell rating on the shares. The company reported Q1 financial results with continued strength from Translarna and Emflaza, leading to a top-line beat, the analyst tells investors in a research note. The firm, however, remains cautious on shares given the commercial headwinds facing its Duchenne muscular dystrophy franchise.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics Q1 Financial Results Conference Call
- PTC Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
- PTC Therapeutics submits MAA for sepiapterin in PKU to EMA
- Cantor Fitzgerald biotech analyst holds an analyst/industry conference call
- PTC Therapeutics provides regulatory updates